Rezim Tablet 80 mg contains Resmetirom, a selective thyroid hormone receptor‑β (THR‑β) agonist developed to manage non‑alcoholic steatohepatitis (NASH) — a serious form of non‑alcoholic fatty liver disease (NAFLD). NASH is characterized by excessive liver fat, inflammation, and fibrosis (scarring) not caused by alcohol use. Rezim targets the underlying metabolic dysfunction in NASH by promoting fat breakdown, improving lipid metabolism, and reducing liver inflammation and fibrosis.

This higher‑strength formulation is designed for patients who require a greater pharmacologic effect to achieve therapeutic goals. Rezim 80 mg offers enhanced efficacy in reducing liver fat and improving clinical outcomes, particularly in cases where lower doses may be insufficient.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Composition

Each tablet contains:

• Resmetirom 80 mg

Indications

Rezim Tablet 80 mg is indicated for:

• Management of non‑alcoholic steatohepatitis (NASH) in adults

• Reduction of liver fat content in patients with NAFLD/NASH

• Improvement of metabolic abnormalities associated with liver disease, including dyslipidemia

• Supportive therapy in adult patients with NASH and liver fibrosis

• Adjunctive treatment in metabolic liver disorders as prescribed by a physician

Mechanism of Action

Resmetirom is a targeted agonist of thyroid hormone receptor‑β, which is predominantly expressed in the liver. This selective action results in:

• Increased hepatic fat metabolism: Resmetirom stimulates pathways that enhance fatty acid oxidation and breakdown, reducing liver fat accumulation.

• Improved lipid profile: The therapy lowers levels of low‑density lipoprotein (LDL) cholesterol and triglycerides, contributing to cardiovascular and metabolic benefits.

• Anti‑inflammatory effects: By decreasing liver inflammation, Resmetirom helps slow disease progression.

• Antifibrotic activity: The drug may help stabilize or reduce fibrosis, a key determinant of long‑term outcomes in NASH.

The combined effect of these actions addresses core aspects of NASH pathophysiology, making Rezim 80 mg a promising option for long‑term disease management.

Dosage and Administration

• The typical dose is 80 mg once daily, taken orally with or without food.

• Swallow the tablet whole with water; do not crush or chew unless instructed by a healthcare professional.

• The duration of treatment is determined by clinical response and physician guidance; long‑term therapy may be required.

• Regular monitoring of liver function tests, lipid profile, and metabolic parameters is recommended during treatment.

Precautions and Warnings

• Use with caution in patients with thyroid disorders or hormonal imbalances that may interfere with metabolic regulation.

• Not recommended for patients with severe liver impairment unless carefully monitored by a specialist.

• Notify your physician of all concurrent medications to avoid potential interactions.

• Use during pregnancy or breastfeeding only if benefits outweigh risks, under medical supervision.

• Regular follow‑up is essential to assess therapeutic benefit and monitor for side effects.

Possible Side Effects

Rezim Tablet 80 mg is generally well tolerated, but some individuals may experience:

• Mild gastrointestinal discomfort (nausea, abdominal pain)

• Headache

• Fatigue or dizziness

• Alterations in thyroid hormone levels (rare)

• Changes in lipid parameters that require monitoring

Serious adverse effects are uncommon, but any unusual symptoms should be reported to a healthcare provider promptly.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Storage Instructions

• Store below 30°C in a cool, dry place.

• Protect the tablets from light and moisture.

• Keep out of reach of children.

Conclusion

Rezim Tablet 80 mg (Resmetirom) is an advanced therapy for non‑alcoholic steatohepatitis (NASH) that targets core metabolic dysfunction in the liver. By enhancing fat metabolism, improving lipid profiles, and reducing inflammation and fibrosis, Rezim supports meaningful clinical improvement in patients with NASH. When used under appropriate medical supervision, it offers a promising option for long‑term management of this chronic liver disease.